ImmunOs Therapeutics is a clinical-stage biotechnology company.
ImmunOs Therapeutics has raised $11.0M in total funding. The most recent round was Series C. The last funding was announced in September 2024.
ImmunOs Therapeutics's investors include Lightspeed Venture Partners, Samsara BioCapital, redalpine, Mission BioCapital, European Union.
ImmunOs Therapeutics is headquartered in Schlieren, Switzerland.
ImmunOs Therapeutics is a clinical-stage biotechnology company.
ImmunOs Therapeutics is at the Series C stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"ImmunOs Therapeutics — Funding & Investors." VCBacked, September 17, 2024, https://www.vcbacked.co/company/immunos-therapeutics. Accessed September 3, 2026.
VCBacked. (2024). ImmunOs Therapeutics — Funding & Investors. Retrieved September 3, 2026, from https://www.vcbacked.co/company/immunos-therapeutics
{{cite web |title=ImmunOs Therapeutics — Funding & Investors |url=https://www.vcbacked.co/company/immunos-therapeutics |website=VCBacked |access-date=September 3, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated